Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

2) Novo Nordisk's CagriSema (cagrilintide and semaglutide), a fixed-dose combination of an amylin analogue and GLP-1 agonist for obesity ... a once-monthly small interfering RNA (siRNA) therapy ...

The small, 48-subject study – published ... CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will investigate its effects ...

Small molecules are low molecular weight molecules that include lipids, monosaccharides, second messengers, other natural products and metabolites, as well as drugs and other xenobiotics. They are ...

When interest rates are low, small-cap stocks begin to shine and outpace larger companies in value. These stocks are stocks with a market capitalization between $300 million and $3 billion.

IPC Indice de Precios Y Cotizaciones 54,096.51-380.23-0.70% ...